Angravid in oral contraception. Clinical remarks
Wieczorek, E.; Cislo, M.
Ginekologia Polska 46(9): 995-999
1975
ISSN/ISBN: 0017-0011 PMID: 1176035 Document Number: 89001
53 healthy women, aged 19-42 years, using the Polish oral contraceptive Angravid, were subjected to hematological examinations through the course of 300 menstrual cycles. The drug, which has a smaller content of estrogen than most oral contraceptives, proved to be 100% effective and was well tolerated. Compared with other preparations, such as Femigen, Ovulen, and Bisecurin, it was shown that Angravid is not free of side effects, but that they are less frequent and serious than with the others. No significant alterations were revealed in tests concerning hemopoesis, blood clotting, electrolytes, and liver function. As the testing of this preparation lasted for only 6 months, further, more comprehensive testing is recommended.